StockData
BioCryst Pharmaceuticals Inc logo

BioCryst Pharmaceuticals Inc (BCRX) stock

BCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30
$7.50+0.05 (+0.67%)

Close on Nov 17, 2026Market cap $1.92BP/E –Yield –

BioCryst Pharmaceuticals cash

Cash and short-term investments held at the end of each period.

BioCryst Pharmaceuticals's cash was $352.57M at Jun 30, 2026. For fiscal 2025 it was $274.75M, down 14.8% from the year before. Over ten years it grew 18.2% a year on average. The highest annual figure on record is $507.60M in fiscal 2021.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$274.75M-14.8%
FY2024Dec 31, 2024$322.46M-17.1%
FY2023Dec 31, 2023$388.99M-8.6%
FY2022Dec 31, 2022$425.78M-16.1%
FY2021Dec 31, 2021$507.60M+69.0%
FY2020Dec 31, 2020$300.37M+120.5%
FY2019Dec 31, 2019$136.23M+30.4%
FY2018Dec 31, 2018$104.47M-8.7%
FY2017Dec 31, 2017$114.40M+109.3%
FY2016Dec 31, 2016$54.65M+6.0%
FY2015Dec 31, 2015$51.56M-29.1%
FY2014Dec 31, 2014$72.77M+91.2%
FY2013Dec 31, 2013$38.06M+6.9%
FY2012Dec 31, 2012$35.60M-14.7%
FY2011Dec 31, 2011$41.72M-22.7%
FY2010Dec 31, 2010$53.95M+31.2%
FY2009Dec 31, 2009$41.13M+84.1%
FY2008Dec 31, 2008$22.34M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$352.57M+35.6%
Q1 FY2026Mar 31, 2026$238.40M-19.2%
Q4 FY2025Dec 31, 2025$274.75M-14.8%
Q3 FY2025Sep 30, 2025$212.87M-35.5%
Q2 FY2025Jun 30, 2025$260.04M-4.4%
Q1 FY2025Mar 31, 2025$295.09M-12.3%
Q4 FY2024Dec 31, 2024$322.46M-17.1%
Q3 FY2024Sep 30, 2024$330.01M-17.0%
Q2 FY2024Jun 30, 2024$272.03M-33.8%
Q1 FY2024Mar 31, 2024$336.55M-15.5%
Q4 FY2023Dec 31, 2023$388.99M-8.6%
Q3 FY2023Sep 30, 2023$397.59M-6.9%
Q2 FY2023Jun 30, 2023$410.67M-1.6%
Q1 FY2023Mar 31, 2023$398.16M-10.2%
Q4 FY2022Dec 31, 2022$425.78M-16.1%
Q3 FY2022Sep 30, 2022$426.86M+113.9%
Q2 FY2022Jun 30, 2022$417.48M+91.1%
Q1 FY2022Mar 31, 2022$443.47M+84.5%
Q4 FY2021Dec 31, 2021$507.60M+69.0%
Q3 FY2021Sep 30, 2021$199.60M+39.3%
Q2 FY2021Jun 30, 2021$218.43M+15.3%
Q1 FY2021Mar 31, 2021$240.36M+112.6%
Q4 FY2020Dec 31, 2020$300.37M+120.5%
Q3 FY2020Sep 30, 2020$143.32M+109.4%
Q2 FY2020Jun 30, 2020$189.40M+105.5%
Q1 FY2020Mar 31, 2020$113.06M+5.1%
Q4 FY2019Dec 31, 2019$136.23M+30.4%
Q3 FY2019Sep 30, 2019$68.44M-43.1%
Q2 FY2019Jun 30, 2019$92.15M+14.1%
Q1 FY2019Mar 31, 2019$107.56M+17.8%
Q4 FY2018Dec 31, 2018$104.47M-8.7%
Q3 FY2018Sep 30, 2018$120.32M-25.6%
Q2 FY2018Jun 30, 2018$80.74M+0.1%
Q1 FY2018Mar 31, 2018$91.31M-7.5%
Q4 FY2017Dec 31, 2017$114.40M+109.3%
Q3 FY2017Sep 30, 2017$161.62M+206.0%
Q2 FY2017Jun 30, 2017$80.67M–
Q1 FY2017Mar 31, 2017$98.68M–
Q4 FY2016Dec 31, 2016$54.65M–
Q3 FY2016Sep 30, 2016$52.82M–

More BioCryst Pharmaceuticals figures

See a number that looks wrong?